Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1963 1
1964 2
1990 3
1991 1
1993 1
1995 1
1996 3
1997 1
1998 3
2000 1
2001 4
2002 3
2003 1
2004 1
2007 2
2008 4
2010 2
2013 2
2014 2
2017 5
2018 3
2019 4
2020 4
2021 5
2022 4
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Directed recurrence networks.
Delage R, Nakata T. Delage R, et al. Chaos. 2023 Nov 1;33(11):113103. doi: 10.1063/5.0173394. Chaos. 2023. PMID: 37909898
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, Leber B, Kim DDH. Perusini MA, et al. Among authors: delage r. Br J Haematol. 2023 Dec;203(5):781-791. doi: 10.1111/bjh.19058. Epub 2023 Sep 11. Br J Haematol. 2023. PMID: 37697469
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
Pelland AA, Deschênes-Simard X, Savard X, Giguère P, Spillane D, Barabé F, Laroche V, Munger M, Gallagher G, Marcoux N, Cantin G, Chénard-Poirier M, Delage R, Lalancette M, Veilleux O, Assouline SE, Lemieux C. Pelland AA, et al. Among authors: delage r. Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39129334
Revised 15-item MDS-specific frailty scale maintains prognostic potential.
Wan BA, Nazha A, Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring J, Nevill TJ, Delage R, Elemary M, Banerji V, Parmentier A, Siddiqui M, Kirubananthaan A, Mamedov A, Zhang L, Buckstein R. Wan BA, et al. Among authors: delage r. Leukemia. 2020 Dec;34(12):3434-3438. doi: 10.1038/s41375-020-01026-y. Epub 2020 Aug 28. Leukemia. 2020. PMID: 32855438 No abstract available.
Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pollock C, et al. Among authors: delage r. Clin J Am Soc Nephrol. 2008 Jan;3(1):193-9. doi: 10.2215/CJN.02440607. Clin J Am Soc Nephrol. 2008. PMID: 18178785 Review.
70 results